Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
2 October 2014
Oryzon presentation at the B-debate 50 YEARS OF HISTONE ACETYLATION Barcelona Conference on Epigenetics and Cancer celebrated in CaixaForum, Barcelona.
23 September 2014
ORYZON reinforces its Board of Directors
7 July 2014
ORYZON will participate at the 5th Annual EpiCongress in Boston, Massachusetts
7 April 2014
Roche and Oryzon announce collaboration to develop epigenetics-based medicines
16 January 2014
ORYZON receives approval from MHRA to initiate Clinical Development of ORY-1001, a Novel LSD1 Inhibitor, in Patients with Acute Myeloid Leukemia in the United Kingdom
7 January 2014
ORYZON Initiates Clinical Development of ORY-1001, a Novel LSD1 Inhibitor, in Patients with Acute Myeloid Leukemia
16 December 2013
Oryzon to attend the 32nd ANNUAL J.P. MORGAN Healthcare Conference in San Francisco
15 July 2013
Oryzon obtains orphan designation for ORY-1001 for the treatment of Acute Myeloid Leukemia from the European Medicines Agency
3 June 2013
Oryzon gets its first Patent in the US
17 May 2013
Oryzon to Present at BioEquity Europe 2013 in Stockholm
Pages
« first
‹ previous
…
8
9
10
11
12
13
14
15
16
next ›
last »